PT26 Cost-Effectiveness Analysis of Sunvozertinib as a Second-line Treatment for Advanced Non-Small Cell Lung Cancer with EGFR exon20ins Mutation: An Economic Evaluation Based on MAIC
Jul 1, 2025, 00:00
10.1016/j.jval.2025.04.2131
https://www.valueinhealthjournal.com/article/S1098-3015(25)02260-0/fulltext
Title :
PT26 Cost-Effectiveness Analysis of Sunvozertinib as a Second-line Treatment for Advanced Non-Small Cell Lung Cancer with EGFR exon20ins Mutation: An Economic Evaluation Based on MAIC
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(25)02260-0&doi=10.1016/j.jval.2025.04.2131
First page :
Section Title :
Open access? :
No
Section Order :
10304